The Pharmacy Times® Gastrointestinal resource center provides news and articles centered around the FDA approved drugs in gastroenterology, as well as links to condition-specific resources, and videos and other content.
What can we help you find?
Diet and lifestyle changes are key components of treating gastroesophageal reflux disease.
Pharmacists can, and should, play an important role in counseling patients before they travel anywhere about what to do in the event of a GI illness while vacationing.
Why is this healthy young man getting frequent food poisoning?
Travel health services involves a lot more than vaccinations, said Sheri Stensland, PharmD, in a session at McKesson ideaShare.
Parvus Therapeutics and Genentech have entered into a worldwide collaboration and licensing agreement for the development, manufacturing, and commercialization of treatments for inflammatory bowel disease, autoimmune liver diseases, and celiac disease using nanomedicines (Navacim) developed by Parvus.
If approved, Gimoti would be the first non-oral drug treatment for symptoms associated with acute and recurrent diabetic gastroparesis in adult women and would represent the first significant advancement in the treatment of gastroparesis in 40 years.
The drug is indicated for those patients who were previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Rifamycin's effectiveness was shown in a randomized, placebo-controlled clinical trial during which the drug significantly reduced symptoms of travelers’ diarrhea in adults afflicted with the condition in Guatemala and Mexico.
Opioids are associated with various adverse effects, including constipation, nausea, respiratory depression, sedation, and vomiting.
Officials with the FDA have approved eravacycline (XERAVA, Tetraphase Pharmaceuticals), a fluorocycline antibacterial within the tetracycline class of antibacterial drugs, for the treatment of complicated intra-abdominal infections (cIAI) in patients aged 18 years and older.
The CDC and FDA are currently investigating a multistate outbreak of Cyclospora infections (cyclosporiasis) linked to McDonald’s salads.